Press Releases about Ligand Pharm
![](https://www.marketbeat.com/logos/articles/med_20240709161607_5-best-short-term-stocks-to-consider-investing-in.jpg)
![](https://mms.businesswire.com/media/20240706652097/en/1990362/5/New_Ligand_Logo.jpg)
![](https://ml.globenewswire.com/media/ca940278-cc18-4a3f-93b7-d8a034c998c9/small/lifecore-corporate-logo-2c-png.png)
![](https://mms.businesswire.com/media/20240627518993/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240618130919/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240523216667/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240507633610/en/2123419/5/logo.jpg)
![](https://mms.businesswire.com/media/20240507973195/en/2122485/5/Ligand_full_color_logo_FINAL.jpg)
![](https://mms.businesswire.com/media/20240423025889/en/2106309/5/logo.jpg)
![](https://mms.businesswire.com/media/20240408525422/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240403857451/en/2087841/22/Scott_Plesha_CEO_Pelthos_Therapeutics.jpg)
![](https://mms.businesswire.com/media/20240305561022/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240304017350/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240227868201/en/1990362/5/New_Ligand_Logo.jpg)
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Via Business Wire
![](https://mms.businesswire.com/media/20240222424618/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240215878741/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240213620099/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240201924216/en/1990362/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20240105377376/en/1990356/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20231212987229/en/1967452/5/New_Ligand_Logo.jpg)
![](https://mms.businesswire.com/media/20231206842106/en/346436/5/Ligand-Logo-Registered5.jpg)
![](https://ml.globenewswire.com/media/73795541-56ed-4418-88e6-64a98922589f/small/palvella-logo-png.png)
![](https://mms.businesswire.com/media/20231108320171/en/346436/5/Ligand-Logo-Registered5.jpg)
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
Via Business Wire
![](https://mms.businesswire.com/media/20231101846503/en/346436/5/Ligand-Logo-Registered5.jpg)
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
Via Business Wire
![](https://mms.businesswire.com/media/20231025648141/en/346436/5/Ligand-Logo-Registered5.jpg)
![](https://ml.globenewswire.com/media/683042b5-bcb5-4ce5-84d4-2fbe238479cb/small/ovid-registered-logo-jpg.jpg)
![](https://mms.businesswire.com/media/20230927379411/en/346436/5/Ligand-Logo-Registered5.jpg)
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
September 27, 2023
Via Business Wire
![](https://mms.businesswire.com/media/20230926107866/en/346436/5/Ligand-Logo-Registered5.jpg)
Ligand Appoints Martine Zimmermann to its Board of Directors
September 26, 2023
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.